Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome.

ABSTRACT:

Background

Schistosomiasis is a neglected tropical disease burdening millions of people. One drug, praziquantel, is currently used for treatment and control. Clinically relevant drug resistance has not yet been described, but there is considerable heterogeneity in treatment outcomes, ranging from cure to only moderate egg reduction rates. The objectives of this study are to investigate potential worm-induced dysbacteriosis of the gut microbiota and to assess whether a specific microbiome profile could influence praziquantel response.

Methods

Using V3 and V4 regions of 16S rRNA genes, we screened the gut microbiota of 34 Schistosoma mansoni infected and uninfected children from Côte d'Ivoire. From each infected child one pre-treatment, one 24-hour and one 21-day follow-up sam

SUBMITTER: Schneeberger PHH 

PROVIDER: S-EPMC5848565 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature